PD-L1 expression with immune-infiltrate evaluation and outcome prediction in melanoma patients treated with ipilimumab.
Publication Title
Oncoimmunology
Authors
Gabriele Madonna
Carmen Ballesteros-Merino, Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Providence Cancer Center, Providence Portland Medical Center, Portland, OR, USA.Follow
Zipei Feng, Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Providence Cancer Center, Providence Portland Medical Center, Portland, OR, USA; Department of Cancer Biology, Oregon Health & Science University, Portland, OR, USA.Follow
Carlo Bifulco, Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Providence Cancer Center, Providence Portland Medical Center, Portland, OR, USA; Department of Pathology, Providence Portland Medical Center, Portland, OR, USA.Follow
Mariaelena Capone
Diana Giannarelli
Domenico Mallardo
Ester Simeone
Antonio M Grimaldi
Corrado Caracò
Gerardo Botti
Bernard A Fox, Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Providence Cancer Center, Providence Portland Medical Center, Portland, OR, USA; Department of Molecular Microbiology & Immunology, Oregon Health & Science University, Portland, OR, USA.Follow
Paolo A Ascierto
Publication Date
1-1-2018
Keywords
Immunotherapy; Ipilimumab; Melanoma; PD-L1; Tumor microenvironment; genomics
Clinical Institute
Cancer
Specialty/Research Institute
Earle A. Chiles Research Institute
Specialty/Research Institute
Oncology
